The global Proprotein Convertase Subtilisin/Kexin Type 9 market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Proprotein Convertase Subtilisin/Kexin Type 9 volume and value at global level, regional level and company level. From a global perspective, this report represents overall Proprotein Convertase Subtilisin/Kexin Type 9 market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Proprotein Convertase Subtilisin/Kexin Type 9 in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Proprotein Convertase Subtilisin/Kexin Type 9 manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
AFFiRiS AG
Betagenon AB
Bioleaders Corp
BioLingus AG
Catabasis Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Eli Lilly and Co
Ensemble Therapeutics Corp
Kowa Co Ltd
Novartis AG
Pfizer Inc
Regeneron Pharmaceuticals Inc
Serometrix LLC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
The Medicines Company

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
SX-PCK9
O-304
K-312
BLSM-201
DCRPCSK-9
Others

Segment by Application
Cardiovascular Disease
Homozugous Familial Hyperchalesterolemia
Liver Disease
Metabolic Syndrome
Others